Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Teva Plans Copaxone sNDA For Earlier Use In MS Patients After First Clinical Event

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Filing is based on interim analysis of a trial showing glatiramer reduced risk of developing clinically definite multiple sclerosis.

You may also be interested in...



High Copaxone Dose Fails To Show Superiority In MS, Teva Says

In Phase III, 40 mg dose did not reduce relapse rate in patients over the approved 20 mg strength.

High Copaxone Dose Fails To Show Superiority In MS, Teva Says

In Phase III, 40 mg dose did not reduce relapse rate in patients over the approved 20 mg strength.

Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

Compound fails to meet primary and secondary trial endpoints.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS065583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By